In this study, we demonstrate the function of PRPK in both tumor growth and the immune environment, which offers an opportunity to develop dual-action therapies capable of addressing both the intrinsic drivers of cancer and the extrinsic immunosuppressive environment. Here, TP53RK is linked to cancer.